Skip to main content

TATAA Biocenter Using Ingenuity Systems Software in HT Gene Expression Profiling


TATAA Biocenter said today that it has begun using Ingenuity Systems' iReport software in high-throughput gene expression profiling workflows.

The combined solution enables TATAA Biocenter's laboratories to provide contract research for a full range of real-time qPCR services — including primer and probe design, validation, kit and instrument evaluation, and biological and statistical analysis.

TATAA Biocenter offers all of the instrumentation and sample handing necessary to perform high-quality qPCR experiments, and meets specific requirements for compliance with ISO 17025. Ingenuity iReport enables researchers to quickly and easily identify significant differentially expressed genes and interpret the impact of those expression changes in the context of pathways, phenotypes, and molecular interactions.

Mikael Kubista, founder and CEO of TATAA Biocenter, said in a statement that TATAA decided on iReport for pathway analysis because it provides a "smooth workflow" with data collected on the biocenter's Life Technologies OpenArray and Fluidigm BioMark high-throughput qPCR platforms; reads batchwise into GenEx software for multivariate statistical analysis, and provides "an easy, accurate, web-based biological and statistical interpretation tool."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.